

MarketVue®

# Pancreatic Ductal Adenocarcinoma (PDAC)

November 2022



# MarketVue®: Pancreatic Ductal Adenocarcinoma

## UNDERSTAND THE PDAC MARKET

**MarketVue** market landscape reports combine primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.

Every **MarketVue** includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

**Methodology:** Research is supported by 7 qualitative interviews with key opinion leaders (4 U.S. oncologists, 1 UK oncologist, 1 French oncologist, and 1 Italian oncologist), a quantitative survey with 23 U.S. physicians and secondary research.

**Geographies covered:** United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

### TOPICS COVERED

**EPIDEMIOLOGY:** Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments

**CURRENT TREATMENT:** Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment

**UNMET NEEDS:** Identify opportunities to address treatment or disease management gaps

**PIPELINE ANALYSIS:** Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs

**VALUE AND ACCESS:** Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

## Why MarketVue?

- **PMR-Driven** – Insights informed by qualitative interviews and/or quantitative surveys
- **Senior Team** – Experienced team members (10+ years in pharma market research) lead the research
- **Strategic** – Delivered in a concise and strategic report template vetted by pharmaceutical industry professionals
- **Fresh** – New reports or report refreshes delivered in as little as 15 business days



# MarketVue®: Pancreatic Ductal Adenocarcinoma

UNDERSTAND THE PDAC MARKET

## COMPANIES MENTIONED

- Novartis
- Pancreatic Cancer Action Network
- Panbela Therapeutics
- BioLineRx
- Astellas Pharma
- TME Pharma
- Merck Sharp & Dohme
- SynerGene Therapeutics
- Ability Pharma
- AstraZeneca
- ERYTECH
- Cornerstone Pharmaceuticals
- Eli Lilly
- Pharmacyclics
- Halozyme Therapeutics
- Sumitomo Pharma

## DRUGS MENTIONED

- Capecitabine
- FOLFIRINOX
- Gemcitabine
- Cisplatin
- Olaparib (Lynparza)
- Larotrectinib (Vitrakvi)
- Entrectinib (Rozlytrek)
- Pembrolizumab (Keytruda)
- Pamrevlumab
- Canakinumab (Ilaris)
- Spartalizumab
- SM-88
- Ivospemin
- Zolbetuximab
- Olaptosed pegol
- SGT-53
- ABTL0812
- Selumetinib (Koselugo)
- Durvalumab (Imfinzi)
- Paclitaxel (Abraxane)
- Eryaspase
- Devimistat
- Pegilodecakin
- Ibrutinib (Imbruvica)
- PEGPH20
- Napabucasin

# MarketVue®: Pancreatic Ductal Adenocarcinoma

## Table of Contents

<b>1. DISEASE OVERVIEW</b>	<b>5 - 6</b>
An aggressive, lethal cancer beginning in the ducts of the pancreas	5
Figure 1.1. Signs and symptoms of PDAC	5
Table 1.1. Risk factors associated with PDAC	5
PDAC is a lethal cancer with limited treatments but many potentially actionable targets	6
Table 1.2. Staging of disease in PDAC	6
Table 1.3. Five-year survival rates for pancreatic cancer	
<b>2. EPIDEMIOLOGY &amp; PATIENT POPULATIONS</b>	<b>7 - 8</b>
Disease definition	7
Table 2.1. Incident populations of PDAC in the US, EU4 and UK	7
Drug-treated PDAC patients	8
Table 2.2. Drug-eligible and drug-treated PDAC patients by stage	8
<b>3. DIAGNOSIS AND CURRENT TREATMENT</b>	<b>9 - 19</b>
Diagnosis Overview	9
Figure 3.1. Oncologist-reported PDAC patient segmentation	9
Diagnostic journey of PDAC patients – timely diagnosis is challenging due to the nature of the symptoms	10
Treatment flows for resectable and borderline resectable patients	11
Table 3.1. Surgery-eligible PDAC patient segments	11
Treatment of resectable and borderline resectable PDAC	12
Figure 3.2. Neoadjuvant therapy use prior to surgery in surgery-eligible PDAC patients	12
Figure 3.3. Adjuvant therapy in patients who have undergone resection	12
Physician insights on drug treatment in surgery-eligible patients	13
Treatment of locally advanced and metastatic patients	14
Table 3.2. Unresectable PDAC patient segments	14
Treatment of metastatic patients	15
Figure 3.4. Percentage of oncologists who prescribe Olaparib to BRCA+ patients as a maintenance tx	15
FOLFIRNIOX and gemcitabine-based therapies are the backbone of PDAC treatment	16
Figure 3.5. Oncologist-reported current treatment share for locally advanced and metastatic patients: 1 <sup>st</sup> -line setting	16
Figure 3.6. Oncologist-reported current treatment share for locally advanced and metastatic patients: 2 <sup>nd</sup> -line setting	16

# MarketVue®: Pancreatic Ductal Adenocarcinoma

## Table of Contents

Identification of druggable targets guides treatment decisions in unresectable patients	17
Table 3.3. Genetic and somatic testing of PDAC patients	17
Figure 3.7. Oncologist-reported percentage of PDAC patients tested for germline and somatic mutations	17
Key treatment dynamics that shape disease management and drug use in PDAC	18
Table 3.4. Must-know PDAC treatment dynamics for now and the future	18
PDAC market evolution	19
Figure 3.8. Important dynamics of PDAC market evolution	19
<b>4. UNMET NEED</b>	<b>20 - 22</b>
Overview	20
Figure 4.1. Top unmet needs in PDAC	20
Figure 4.2. Medical Oncologist unmet needs in PDAC	20
Unmet needs – Physician perspectives	21
Clinical outcomes that impact prescribing habits – Physician perspectives	22
Figure 4.3. Importance of clinical outcomes on prescribing habits in 1st and 2nd line mPDAC	22
<b>5. PIPELINE ANALYSIS</b>	<b>23 - 28</b>
Overview	23
Figure 5.1. Percentage of oncologists rating target as “promising” for PDAC	23
Physician commentary on emerging therapy targets	24
Late-stage clinical development for metastatic PDAC	25
Table 5.1. Comparison of selected late-stage trials in metastatic PDAC	25
Early-stage clinical development for metastatic PDAC	26
Table 5.2. Selected ongoing Phase 2 clinical trials	26
Early-stage clinical development for metastatic PDAC (continued)	27
Table 5.2. Selected ongoing Phase 2 clinical trials (continued)	27
Novel therapy trial failure in PDAC and a new approach to trial design	28
Table 5.3. Focus on the Phase 3 CanStem111P study of napabucasin	28
<b>6. VALUE &amp; ACCESS</b>	<b>29</b>
Overview	29
Table 6.1. Current therapy pricing, US 2022	29
Figure 6.1. Reimbursement and Access considerations for emerging therapies in PDAC	29

# MarketVue®: Pancreatic Ductal Adenocarcinoma

## Table of Contents

### **7. METHODOLOGY**

**30 - 33**

Primary market research approach	30
Epidemiology methodology	31
Appendix: List of abbreviations used in PDAC report	32
Appendix: List of abbreviations used in PDAC report (continued)	33

# Meet the REACH Team



**DANIELLE DRAYTON, PhD.**, Dr. Drayton is CEO and Founder of REACH Market Research. She is a seasoned business leader and pharmaceutical market researcher. Prior to founding REACH, Dr. Drayton led the Biopharma Market Assessment business at Decision Resources Group (DRG) comprised of market research, RWD analytics, and consulting business lines. In her 14 years at DRG, she worked with 48 of the top 50 pharmaceutical companies and countless biotech companies that involved exhaustive evaluation of unmet need, target product profiles, commercial potential and new product adoption, and company competitiveness. She also has extensive experience conducting product and market opportunity assessments, portfolio analysis, product and therapeutic area strategy, product valuation and sales forecasting, and pre-launch planning. Dr. Drayton completed a postdoctoral fellowship at the Harvard Medical School, received a Ph.D. in Immunobiology from Yale University, and earned a B.S. in Microbiology and Immunology from the University of Miami (Florida).



**MELISSA CURRAN** is the Director of Product Management at REACH. Melissa has over 10 years of life sciences market research and consulting experience spanning from bespoke strategy consulting to syndicated market research product development and management. Prior to joining REACH, she worked at Decision Resources Group (DRG) for 7 years assisting pharmaceutical and biotechnology commercial teams across the product lifecycle to inform strategic decision making. Melissa is particularly passionate about new product planning and portfolio management, especially in the rare disease space where data can be scarce, and decision-making can be challenging. Specific types of strategic assessments Melissa specializes in include market landscape assessments, commercial opportunity assessment, patient journey mapping, product positioning and TPP optimization, portfolio prioritization, and competitive intelligence. She also has extensive experience working across various market research methodologies including qualitative interviews, quantitative surveys, patient chart audits, real world claims and EHR data, conjoint analysis and secondary research. Melissa received her bachelor's degree in Biology and minor in Business from Providence College.



**MICHAEL HUGHES, MSc, Ph.D.**, Dr. Hughes is the Director of Research at REACH. He has worked in academia, regulatory affairs (NICE) and in RWE and epidemiology consultancies, leading the global epidemiology team at Clarivate (previously Decision Resources Group) for many years. Over that period, he has built numerous new approaches to epidemiological forecasting and imputation, which now form industry best-practice. He has built syndicated and custom epidemiological models and forecasts for many blockbuster drugs across many therapeutic areas, often using a hybrid approach sourcing data from multiple types of dataset and primary market research. He has recently worked on projects in prostate cancer, amyloidosis, anaphylaxis and multi-drug resistant UTIs, among others. He has supported the needs of both big pharma, including Novartis, GSK and Johnson and Johnson, as well as smaller companies and biotechs.

# Meet the REACH Team



**TYLER JAKAB, MPH** is an analyst at REACH Market Research. He is responsible for conducting both primary and secondary market research regarding rare disease therapies to be integrated into market research reports for life science clients. Tyler is a recent graduate of Boston University School of Public Health where he obtained an MPH in Epidemiology of Biostatistics. Prior to joining REACH, he held roles in which he was responsible for health policy analysis, tobacco control research, and health communication. He has extensive experience in data analysis, as well as manuscript and report writing. Tyler also earned a BS in Psychology and Anthropology from the University of North Carolina at Chapel Hill.



**BAYLEY KOOPMAN** is a Research Associate at REACH Market Research. At REACH, Bayley supports both primary and secondary market research through literature reviews and working with qualitative data. He recently graduated from Tufts University with a B.S. in Biology where he studied the interdisciplinary OneHealth approach for public health and the environment. During this time, Bayley founded an early-stage consumer product startup, which became a finalist team in two consecutive Tufts University Entrepreneurship Pitch Competitions. Prior to joining REACH, Bayley also held roles in regulatory affairs in the rare-disease pharmaceutical industry and veterinary practice.



**BRIANA MULLINS** is a current PhD student At NYU School of Medicine studying the immunological progression of disease in psoriatic arthritis. She currently does both laboratory research and computational biology. Previously she earned her undergraduate degree in Biochemistry at New York University (NYU) and worked in the Blaser Lab studying the human microbiome. She also received an MSc. in Population Health at the University College London (UCL) and conducted antibiotic prescription research using the UK THIN Database. Before starting her PhD Briana worked at Decision Resources Group as an Associate Epidemiologist.